Radj Gervais

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella et al. · Journal of Clinical Oncology · 2004 · 2.4K citations · Full text

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

David M. Hyman, Igor Puzanov, Vivek Subbiah et al. · New England Journal of Medicine · 2015 · 1.7K citations · Full text

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok et al. · The Lancet · 2008 · 1.2K citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +9

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

Medicine, Pathology, Pleural Disease +5